Expression levels of p16 and TOP2A biomarkers have been reported for early diagnosis of cervical cancer in high-resource countries, [14, 15, 22, 25] which necessitates the need for their feasibility study in low-resource settings. This evidence concerns the gene TOP2A and cervical carcinoma.